Merck & Co. (MRK) is Greylin Investment Mangement Inc.’s 7th Largest Position
Greylin Investment Mangement Inc. cut its position in Merck & Co. (NYSE:MRK) by 0.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 300,351 shares of the company’s stock after selling 1,925 shares during the period. Merck & Co. makes up approximately 4.3% of Greylin Investment Mangement Inc.’s holdings, making the stock its 7th largest position. Greylin Investment Mangement Inc.’s holdings in Merck & Co. were worth $17,303,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Raymond James Trust N.A. boosted its stake in shares of Merck & Co. by 3.3% in the second quarter. Raymond James Trust N.A. now owns 337,745 shares of the company’s stock worth $19,457,000 after buying an additional 10,865 shares in the last quarter. Nordea Investment Management AB boosted its stake in Merck & Co. by 16.1% in the second quarter. Nordea Investment Management AB now owns 2,411,985 shares of the company’s stock worth $138,954,000 after buying an additional 334,806 shares during the period. Orbis Allan Gray Ltd purchased a new stake in Merck & Co. during the first quarter worth about $239,761,000. Envestnet Asset Management Inc. boosted its stake in Merck & Co. by 7.0% in the first quarter. Envestnet Asset Management Inc. now owns 1,107,242 shares of the company’s stock worth $58,584,000 after buying an additional 72,808 shares during the period. Finally, Avalon Advisors LLC boosted its stake in Merck & Co. by 1.1% in the first quarter. Avalon Advisors LLC now owns 522,566 shares of the company’s stock worth $27,649,000 after buying an additional 5,754 shares during the period. Hedge funds and other institutional investors own 72.93% of the company’s stock.
Shares of Merck & Co. (NYSE:MRK) traded down 3.08% during mid-day trading on Tuesday, hitting $61.93. 13,955,380 shares of the company were exchanged. The company’s 50-day moving average price is $62.68 and its 200-day moving average price is $58.56. The firm has a market capitalization of $171.25 billion, a P/E ratio of 33.97 and a beta of 0.68. Merck & Co. has a 12-month low of $47.97 and a 12-month high of $64.86.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.02. The firm earned $9.84 billion during the quarter, compared to the consensus estimate of $9.79 billion. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The business’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.86 EPS. Equities research analysts predict that Merck & Co. will post $3.75 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 15th were issued a $0.46 dividend. This represents a $1.84 dividend on an annualized basis and a yield of 2.97%. The ex-dividend date of this dividend was Tuesday, September 13th. Merck & Co.’s dividend payout ratio is currently 101.10%.
A number of equities research analysts have issued reports on the stock. Piper Jaffray Cos. restated a “neutral” rating and set a $62.00 price target (up from $58.00) on shares of Merck & Co. in a report on Monday, August 8th. Vetr cut shares of Merck & Co. from a “buy” rating to a “hold” rating and set a $64.84 price target for the company. in a report on Monday. Argus restated a “buy” rating and set a $65.00 price target on shares of Merck & Co. in a report on Wednesday, September 14th. Jefferies Group restated a “hold” rating and set a $56.00 price target (down from $57.00) on shares of Merck & Co. in a report on Monday, September 12th. Finally, BMO Capital Markets cut shares of Merck & Co. from an “outperform” rating to a “market perform” rating and set a $62.00 price target for the company. in a report on Monday, July 18th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of €63.37 ($70.41).
In other Merck & Co. news, insider Weir Mirian M. Graddick sold 40,800 shares of the business’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of €62.07 ($68.97), for a total value of €2,532,456.00 ($2,813,840.00). Following the completion of the sale, the insider now owns 128,973 shares of the company’s stock, valued at approximately €8,005,354.11 ($8,894,837.90). The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Kenneth C. Frazier sold 392,000 shares of the business’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of €61.81 ($68.68), for a total transaction of €24,229,520.00 ($26,921,688.89). Following the completion of the sale, the chairman now directly owns 760,877 shares of the company’s stock, valued at approximately €47,029,807.37 ($52,255,341.52). The disclosure for this sale can be found here. 0.05% of the stock is currently owned by company insiders.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Stock Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related stocks with our FREE daily email newsletter.